Continuous joint use of estrogen and progestin lowers risk of EC in postmenopausal women

December 14, 2015, Oxford University Press

Adding continuous progestin to estrogen has been shown to lower the risk of endometrial cancer in postmenopausal women according to a study published December 14 in the JNCI: Journal of the National Cancer Institute.

The addition of to an regimen has been known to lower the risk of which are associated with estrogen alone use but just how much the addition of progestin lowers the risk of getting the disease has remained unclear.

In order to determine the effects that continuous estrogen plus progestin use has on the risk of endometrial cancer, Rowan T. Chlebowski, M.D., Ph.D., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and colleagues reviewed data from a randomized clinical trial by the Women's Health Initiative (WHI) that assessed 16,608 postmenopausal women aged 50-79 with intact uteri. All participants were required to have a normal endometrial biopsy on entry and were randomly assigned to daily estrogen plus progestin (given as one pill) or placebo (no hormones) and followed over a period of 13 years.

The researchers found that there was a statistically significant reduction in endometrial cancer incidence, after 5.6 years' median intervention and 13 years' cumulative follow-up, in the group that received combination estrogen plus progestin therapy (33 cases, 0.06% yearly) compared to those who received the placebo (95 cases, 0.10% yearly). "Continuous combined estrogen plus progestin use for 5.6 years in postmenopausal women with normal endometrial biopsy at therapy initiation resulted in a statistically significant reduction in endometrial cancer incidence, with the difference becoming statistically significant during longer-term post intervention follow-up," the authors write, adding that, "in , continuous combined estrogen plus progestin use reduces endometrial cancer incidence by 35%."

Explore further: More analysis from the women's health initiative on hormones, breast cancer

More information: Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial, DOI: 10.1093/jnci/djv350

Related Stories

More analysis from the women's health initiative on hormones, breast cancer

April 16, 2015
Analysis of the longer-term influence of menopausal hormone therapy on breast cancer incidence in two Women's Health Initiative (WHI) clinical trials suggests a pattern of changing influences over time on breast cancer, according ...

Menopausal hormone therapy and breast cancer risk

March 15, 2012
In the past decade, results from large prospective cohort studies and the Women's Health Initiative (WHI) randomized placebo-controlled hormone therapy trials have substantially changed thoughts about how estrogen alone and ...

Female hormone supplements with estrogen and progestin linked to breast cancer risk

November 30, 2015
Postmenopausal African American women who use female hormone supplements containing estrogen and progestin ("combination" therapy) are at an increased risk for estrogen receptor positive breast cancer.

Estrogen plus progestin use linked with increased breast cancer incidence and mortality

March 29, 2013
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be ...

VTE risk varies by hormone therapy formulation

September 18, 2012
(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.